Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Weill Cornell Med College

Neither a doctor nor a teaching hospital

Research payments

$14,514,058

55 payments

Through program year 2023, Weill Cornell Med College is reported as receiving $14,514,058 in research payments, across 55 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $1,481,762 5
2022 Research $6,422,538 7
2021 Research $4,288,016 9
2020 Research $2,008,173 14
2019 Research $313,569 20

Breakdown

Who paid Research payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $13,433,406 34 payments
  2. Acerta Pharma LLC $1,031,400 16 payments
  3. Alexion Pharmaceuticals, Inc. $45,000 1 payment
  4. AstraZeneca UK Limited $4,252 4 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Multicenter Phase 2 Study of Acalabrutinb, Lenalidomide, Rituximab with Real Time MRD Monitoring in Patients with Previous Untreated MCL $11,564,167 9 payments
  2. A Phase 1 Multicenter Open label and Dose escalation Study of ACP196 in Subjects with Chronic Lymphocytic Leukemia Richters Syndrome or Prolymphocytic Leukemia $908,785 5 payments
  3. Phase II Trial of Carboplatin, Etoposide, and Durvalumab with Sub-Ablative SBRT in Patients with Newly Diagnosed Stage IV Small Cell Lung Cancer $851,063 3 payments
  4. RANDOMIZED PHASE II TRIAL OF PREOPERATIVE medi 4736 WITH OR WITHOUT CONCURRENT SUB ABLATIVE HYPO FRACTIONATED RADIOTHERAPY IN PATIENTS WITH CLINCIAL STATE I II NON SMALL CELL LUNG CANCER $813,146 4 payments
  5. Study of MEDI4736 Durvalumab With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer $123,325 6 payments
  6. An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenstrom Macroglobulinemia $75,549 5 payments
  7. Decision tree analysis to determine optimal treatment duration in aHUS $45,000 1 payment
  8. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $20,294 3 payments
  9. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $18,029 2 payments
  10. Dapagliflozin in Acute Decompensated Heart Failure $14,875 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record